Sign up USA
Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

ImmuPharma PLC | Synairgen plc | Tissue Regenix Group PLC | WideCells Group

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.

 

This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.

 

The event is not suitable for people pursuing commercial opportunities.


Register


ImmuPharma PLC

RSS Portfolio

imm.gif


ImmuPharma PLC is a pharmaceutical company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The company’s most advanced drug candidate recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and “Fast Track” designation. ImmuPharma is led by a commercially focused Board and management team with extensive experience.

ImmuPharma is traded in the NEX Exchange HERE

EPIC: IMM
Market: AIM
52-week High/Low: 103.50p / 31.44p
Market Cap: 130.54M


View full company profile

Synairgen plc

RSS Portfolio

synairgen-latest.jpg


Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic.

The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease.

Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development.

Core to Synairgen’s business strategy is the realisation of value via licensing transactions – as demonstrated through the out-licensing of SNG001 to AstraZeneca in 2014 in a deal worth up to $232m plus royalties.

Synairgen is quoted on the London Stock Exchange (LSE:SNG).

EPIC: SNG
Market: AIM
52-week High/Low: 32.00p / 6.98p
Market Cap: 10.74M


View full company profile

Tissue Regenix Group PLC

RSS Portfolio

tissue_regenix_sponsor_logo.png


Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation (‘dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body which can then be used to repair diseased or worn-out body parts. The potential applications for this process are diverse and address many critical clinical needs such as treating vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

Tissue Regenix is based in York and has an operation in San Antonio, USA

EPIC: TRX
Market: AIM
52-week High/Low: 21.00p / 9.00p
Market Cap: 107.46M


View full company profile

WideCells Group

RSS Portfolio

WideCellsGroup-2.jpg


WideCells Group PLC is a worldwide healthcare services company focused on collecting and storing stem cells and providing ground breaking insurance for stem cell treatment.

 

** Click here to read a full statement from the Group CEO Joao Andrade on the momentous news that WideCells Group has been included in the DISRUPT 100 index as the 21st most disruptive firm in the world **

EPIC: WDC
Market: LSE
52-week High/Low: 16.30p / 11.25p
Market Cap: 8.83M


View full company profile
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use